bbibp-corv
Vaccineexperimental
Clinical trial activity
7 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Aug 3, 2021 (NCT04988048)
Timeline
Indications
Studied for
- Anaphylaxis · Phase 3
- Arthritis, Rheumatoid · Phase 2
- Coronavirus Infections · Phase 3
- COVID-19 · Phase 3
- COVID-19 Vaccines · Phase 2
- Healthy Volunteers · Phase 2
- HIV Infections · Phase 2
- Immunocompromised Host · Phase 2
- Inflammatory Bowel Diseases · Phase 2
- Influenza, Human · Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Transplants · Phase 2
- Vaccines · Phase 3
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06599658 | Phase 2 | Nov 20, 2024 | McGill University |
| NCT05599516 | Phase 3 | Nov 4, 2022 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China |
| NCT05409300 | Phase 2 | Apr 25, 2022 | Alliance for International Medical Action, Government of France, Government of the Republic of Guinea, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé Et de la Recherche Médicale, France, University of Paris |
| NCT05249816 | Phase 3 | Mar 18, 2022 | Cogna Technology Solutions LLC, Novavax, Sheikh Khalifa Medical City |
| NCT05028257 | Phase 3 | Sep 15, 2021 | Assistance Publique - Hôpitaux de Paris |
| NCT05017805 | N/A | Aug 15, 2021 | People's Liberation Army of China |
| NCT04988048 | Phase 2 | Aug 3, 2021 | Government of Argentina, Government of Russia |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alliance for International Medical Action | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Beijing Tiantan Bio Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| Cogna Technology Solutions LLC | For profit | 1 | 1 | 1 | 2022 |
| Government of Argentina | Government | 1 | 1 | 1 | 2021 |
| Government of France | Government | 1 | 1 | 1 | 2022 |
| Government of Russia | Government | 1 | 0 | 1 | 2021 |
| Government of the Republic of Guinea | Government | 1 | 0 | 1 | 2022 |
| Innovative clinical research network in vaccinology (I-REIVAC) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 2022 |
| McGill University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Vaccine and Serum Institute, China | For profit | 1 | 1 | 1 | 2022 |
| Novavax | For profit | 1 | 0 | 1 | 2022 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2021 |
| Sheikh Khalifa Medical City | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2022 |
17 organizations
Page 1 / 1